Contribution of neuroinflammation to changes in [C-11]flumazenil binding in the rat brain: Evaluation of the inflamed pons as reference tissue

Andrea Parente, David Vállez García, Alexandre Shoji, Isadora Lopes Alves, Bram Maas, Rolf Zijlma, Rudi A. J. O. Dierckx, Carlos A. Buchpiguel, Erik F. J. de Vries, Janine Doorduin*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Introduction: [C-11]Flumazenil is a well-known PET tracer for GABA(A) receptors and is mainly used as an imaging biomarker for neuronal loss. Recently, GABAA receptors on immune cells have been investigated as target for modulation of inflammation. Since neuronal loss is often accompanied by neuroinflammation, PET imaging with [C-11]flumazenil is potentially affected by infiltrating immune cells. This may also compromise the validity of using the pons as reference tissue in quantitative pharmacokinetic analysis. This study aims to evaluate whether inflammatory processes in the brain can influence [C-11]flumazenil uptake and affect the outcome of pharmacokinetic modeling when the pons is used as reference tissue.

Methods: The herpes simplex encephalitis (HSE) rat model is known to cause neuroinflammation in the brainstem. Dynamic [C-11]flumazenil PET scans of 60-min, accompanied by arterial blood sampling and metabolite analysis, were acquired at day 6-7 days post-infection of male Wistar rats (HSE, n = 5 and control, n = 6). Additionally, the GABAA receptor was saturated by injection of unlabeled flumazenil prior to the tracer injection in 4 rats per group. PET data were analyzed by pharmacokinetic modeling.

Results: No statistically significant differences were found in the volume of distribution (V-T) or non-displaceable binding potential (BPND) between control and HSE rats in any of the brain regions. Pre-saturation with unlabeled flumazenil resulted in a statistically significant reduction in [C-11]flumazenil V-T in all brain regions. The BPND obtained from SRTM exhibited a good correlation to DVR - 1 values from the two-tissue compartment model, coupled with some level of underestimation.

Conclusion: Reliable quantification [C-11]flumazenil binding in rats can be obtained by pharmacokinetic analysis using the pons as a pseudo-reference tissue even in the presence of strong acute neuroinflammation. (C) 2017 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalNuclear Medicine and Biology
Volume49
DOIs
Publication statusPublished - Jun-2017

Keywords

  • [C-11]flumazenil
  • GABA
  • PET
  • Neuroinflammation
  • Pharmacokinetic modeling
  • Herpes simplex encephalitis
  • POSITRON-EMISSION-TOMOGRAPHY
  • TEMPORAL-LOBE EPILEPSY
  • BENZODIAZEPINE-RECEPTOR
  • C-11 FLUMAZENIL
  • IN-VIVO
  • INFLAMMATORY RESPONSES
  • GABA(A) RECEPTOR
  • CORTICAL DAMAGE
  • ION CHANNELS

Cite this